Key result
Infusion of adeno-associated virus-VLDLR in a murine model of familial hypercholesterolemia resulted in a stable 40% reduction in serum cholesterol and triglycerides over 30 weeks.
Why the study?
Does adeno-associated virus-VLDLR gene therapy reduce serum lipids and atherosclerosis in a murine model of familial hypercholesterolemia?
Does adeno-associated virus-VLDLR gene therapy reduce serum lipids and atherosclerosis in a murine model of familial hypercholesterolemia?
Effect estimate: 40% reduction
AAV-mediated delivery of the VLDLR gene provides prolonged reduction of hyperlipidemia and atherosclerosis in a mouse model of familial hypercholesterolemia, suggesting potential for gene therapy in this condition.
AAV-VLDLR merits further preclinical optimization for hypercholesterolemia; leaves open translation, durability, and safety in humans.
Adeno-associated viral vectors were used to deliver the gene for very-low-density lipoprotein (VLDL) receptor (VLDLR) to liver of a murine model of familial hypercholesterolemia (FH). Infusion of adeno-associated virus-VLDLR into the portal circulation of FH mice resulted in a 40% reduction in serum cholesterol and triglyceride that was stable for the duration of the study (30 weeks). Fractionation of serum lipids revealed a reduction of both VLDL and low-density lipoprotein. Expression of transgene-derived VLDLR was confirmed in livers of recipient animals by Western blot analysis and immunohistochemistry; vector DNA was present at 1 copy/cell. Vector-treated animals had significantly less lipid accumulation in liver and reduced atherosclerosis in the aorta.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2000) studied Familial hypercholesterolemia. Adeno-associated viral vector expressing very-low-density lipoprotein receptor (AAV-VLDLR) was evaluated on Serum cholesterol and triglyceride reduction (40% reduction). Infusion of adeno-associated virus-VLDLR in a murine model of familial hypercholesterolemia resulted in a stable 40% reduction in serum cholesterol and triglycerides over 30 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: